针对NSCLC的ALK抑制剂的进展和扩展:一种双重目标的方法
Shreya Kumari1, Mymoona Akhter2, Ghanshyam Das Gupta1
1Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, 142001, India.
European journal of medicinal chemistry
|May 8, 2025
概括
针对ALK和其他致癌途径的双重抑制剂为高级非小细胞肺癌 (NSCLC) 患者提供了新的希望. 这些新型疗法旨在克服耐药性并提高复杂分子形状的治疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 无细胞淋巴瘤激酶 (ALK) 在非小细胞肺癌 (NSCLC) 的进展中至关重要.
- 目前的ALK抑制剂面临抗药性,导致治疗失败.
- 将ALK与其他致癌途径一起定位是一个有希望的治疗策略.
研究的目的:
- 审查ALK的作用及其与其他抗瘤标的协同作用.
- 总结一下最近在ALK双抑制剂合成方面的进展.
- 为开发基于ALK的新型双重抑制剂提供见解.
主要方法:
- 关于ALK抑制剂和双抑制剂发展的文献综述.
- 设计概念和结构活动关系 (SARs) 的分析.
- 评估临床前和临床数据,包括in silico研究.
主要成果:
- ALK重组驱动NSCLC,现有的抑制剂由于耐药性而表现出局限性.
- 针对ALK和其他途径 (例如ROS1,c-MET,EGFR) 的双重抑制剂正在出现.
- 这些抑制剂旨在增强疗效并克服抵抗机制.
结论:
- 双ALK抑制剂代表了NSCLC治疗的重大进展.
- 进一步研究它们的设计,SAR和临床数据是必不可少的.
- 基于ALK的新型双抑制剂对具有复杂分子形状的患者具有潜力.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.7K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
